- ISIN
- US83444M1018
- CUSIP
- 83444M101
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- IPO Date
- Mar 26, 2024
Highlights
- Market Cap
- $12.91B
- Enterprise Value
- $17.93B
- EPS (TTM)
- $8.17
- PE Ratio
- 9.01
- PEG Ratio
- 0.24
- Total Revenue (TTM)
- $8.26B
- Gross Profit (TTM)
- $4.43B
- EBITDA (TTM)
- $2.62B
- Year Range
- $62.38 - $88.20
- Target Price
- $97.80
- ROA (TTM)
- 10.16%
- ROE (TTM)
- 28.82%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SOLV Performance Chart
Solventum Corp (SOLV) is down 7.2% since the beginning of the year. At $74 per share, SOLV is trading 16.6% below its 52-week high of $88.
Loading charts...
Returns By Period
Solventum Corp (SOLV) has returned -7.17% so far this year and -0.01% over the past 12 months.
Solventum Corp
- 1D
- -2.48%
- 1M
- -4.26%
- YTD
- -7.17%
- 6M
- -8.94%
- 1Y
- -0.01%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SOLV Monthly Returns History
Based on dividend-adjusted daily data since Mar 26, 2024, SOLV's average daily return is -0.02%, while the average monthly return is -0.28%.
Historically, 43% of months were positive and 57% were negative. The best month was Nov 2025 with a return of +23.5%, while the worst month was Mar 2024 at -23.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, SOLV closed higher 49% of trading days. The best single day was Feb 25, 2025 with a return of +9.5%, while the worst single day was Mar 26, 2024 at -12.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.86% | -3.60% | -11.99% | 3.15% | 11.27% | -1.85% | -7.17% | ||||||
| 2025 | 12.11% | 7.68% | -4.65% | -13.05% | 10.54% | 3.76% | -5.91% | 2.42% | -0.12% | -5.42% | 23.49% | -7.06% | 19.95% |
| 2024 | -23.61% | -6.53% | -8.72% | -10.89% | 11.35% | 8.88% | 8.75% | 4.10% | -1.47% | -7.62% | -27.45% |
Benchmark Metrics
Solventum Corp has an annualized alpha of -17.05%, beta of 0.84, and R2 of 0.16 versus S&P 500 Index. Calculated based on daily prices since March 26, 2024.
- This stock participated in 177.33% of S&P 500 Index downside but only 39.46% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.16 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -17.05%
- Beta
- 0.84
- R²
- 0.16
- Upside Capture
- 39.46%
- Downside Capture
- 177.33%
Return for Risk
Risk / Return Rank
SOLV ranks 39 for risk / return — below 39% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Solventum Corp (SOLV) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SOLV | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.03 | ||
| Sortino ratioReturn per unit of downside risk | -2.55 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.37 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | -0.00 | 2.78 | -2.78 |
| Martin ratioReturn relative to average drawdown | -0.00 | 12.44 | -12.44 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Solventum Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Solventum Corp was 47.26%, occurring on Jul 9, 2024. The portfolio has not yet recovered.
The current Solventum Corp drawdown is 19.21%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -47.26%Jul 2024 | 3mo 15d | — | 2y 2moMar 2024 - now |
Drawdown Indicators
| SOLV | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -47.26% | -56.78% | +9.52% |
Max Drawdown (1Y)Largest decline over 1 year | -27.46% | -9.10% | -18.36% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -19.21% | -1.80% | -17.41% |
Average DrawdownAverage peak-to-trough decline | -22.83% | -10.71% | -12.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.15% | 2.03% | +10.12% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Solventum Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Solventum Corp is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for SOLV, comparing it with other companies in the Medical Instruments & Supplies industry. Currently, SOLV has a P/E ratio of 9.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for SOLV compared to other companies in the Medical Instruments & Supplies industry. SOLV currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SOLV relative to other companies in the Medical Instruments & Supplies industry. Currently, SOLV has a P/S ratio of 1.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SOLV in comparison with other companies in the Medical Instruments & Supplies industry. Currently, SOLV has a P/B value of 2.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SOLV
Add Solventum Corp to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SOLV